Summit Therapeutics Inc. (SMMT)

$0.999

+0.01 (+0.69%)
Rating:
Recommendation:
Strong Buy
Symbol SMMT
Price $0.999
Beta 0.998
Volume Avg. 0.19M
Market Cap 98.024M
Shares () -
52 Week Range 0.88-8.385
1y Target Est -
DCF Unlevered SMMT DCF ->
DCF Levered SMMT LDCF ->
ROE -100.17% Strong Sell
ROA -79.43% Strong Sell
Operating Margin -
Debt / Equity 80.84% Buy
P/E -
P/B 1.52 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest SMMT news


Mr. Robert W. Duggan
Healthcare
Biotechnology
NASDAQ Global Market

Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.